Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Faes FarmaXMAD:FAE -1.03%93 EV-to-FCF is 30.06 as of Jul. 21, 2026, which is 31% above its 10-year median of 23.02. GuruFocus rates XMAD:FAE with a GF Score™ of 93/100 and a GF Value™ of €5.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 566 Drug Manufacturers companies, Faes Farma ranks worse than 59.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Faes Farma's Enterprise Value is €1,648.6 Mil.
Faes Farma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €54.8 Mil. Therefore, Faes Farma's EV-to-FCF for today is 30.06.
The historical rank and industry rank for Faes Farma's EV-to-FCF or its related term are showing as below:
XMAD:FAE'
s EV-to-FCF Range Over the Past 10 Years
Min: -949.99 Med: 23.02 Max: 60.4
Current: 30.32
During the past 13 years, the highest EV-to-FCF of Faes Farma was 60.40. The lowest was -949.99. And the median was 23.02.
XMAD:FAE's EV-to-FCF is ranked worse than 59.89% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs XMAD:FAE: 30.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Faes Farma's share price for today is €4.345.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faes Farma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.254.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Faes Farma EV-to-FCF Related Terms
Faes Farma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Faes Farma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faes Farma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Faes Farma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Faes Farma's EV-to-FCF falls into.
Faes Farma's current Enterprise Value is €1,648.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faes Farma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €54.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faes Farma (XMAD:FAE) has a EV-to-FCF of 30.06 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Faes Farma and its competitors. This is 31% above median its historical median of 23.02. According to the industry distribution chart, Faes Farma ranks #339 out of 566 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Faes Farma's EV-to-FCF too high?
Faes Farma's current EV-to-FCF of 30.06 is 31% above median its 10-year median of 23.02. The Drug Manufacturers industry median EV-to-FCF is 20.95. Faes Farma's value of 30.06 is 43.5% above this industry median. Based on the distribution chart, Faes Farma ranks #339 out of 566 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Faes Farma has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Faes Farma ranks #339 out of 566 companies for EV-to-FCF. This places Faes Farma in the lower half of its industry. The industry median EV-to-FCF is 20.95. Faes Farma's value of 30.06 is 43.5% above this benchmark. While the company's 10-year median is 23.02 vs. the industry median of 20.95, Faes Farma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Faes Farma's current EV-to-FCF of 30.06 is 43.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Faes Farma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faes Farma's current EV-to-FCF is 30.06, which is 31% above median its own 10-year median of 23.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.18, compared to a current price of €4.35 — trading 16.1% below its estimated fair value. The current EV-to-FCF is 30.06, which is 31% above median its 10-year median of 23.02 and 43.5% above the Drug Manufacturers industry median of 20.95. Faes Farma's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current EV-to-FCF is 30.06 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Faes Farma (XMAD:FAE) Overvalued in 2026?
Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued.
The current stock price of €4.35 is trading 16.1% below its estimated GF Value™ of €5.18.
GuruFocus considers Faes Farma to be Modestly Undervalued.
Key valuation signals for XMAD:FAE:
EV-to-FCF: 30.06 (31% above median its 10-year median of 23.02)
GF Value™: €5.18 vs. price of €4.35 (16.1% below fair value)
Industry Position: 43.5% above the Drug Manufacturers median (#339 of 566)
No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
93GF Score
Get the complete analysis for XMAD:FAE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:FAE has been successfully added to your 
